Skip to content
DraconiticResearch
Search Sources API
226,742 studies31 sourcesUpdated 34 min ago
Peer-reviewedCC BY-NC-ND 4.0Critical Care

Dynamic reprogramming of alveolar epithelial-immune cell interactions in ARDS: from mechanisms to clinical translation

  1. 1Department of Critical Care Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, No. 1 Shuaifuyuan, Dongcheng District, Beijing, 100730 China
  2. 2Center for Biomarker Discovery and Validation, National Infrastructures for Translational Medicine, Institute of Clinical Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China

Abstract

Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome characterized by disruption of the alveolar-capillary barrier and refractory hypoxemia. Despite advances in supportive care, effective targeted therapies remain lacking. A major challenge to therapeutic success is the marked heterogeneity of ARDS, in which distinct biological mechanisms may drive different etiologies, inflammatory subphenotypes, and disease stages. Increasing evidence suggests that alveolar epithelial cells (AECs) are not merely passive targets of injury but active regulators of immune responses. Dynamic interactions between AECs and macrophages, neutrophils, and lymphocytes occur throughout the course of ARDS and contribute to inflammatory amplification, tissue repair, and aberrant remodeling. In this review, we summarize epithelial-immune interaction patterns across the inflammatory exudative, proliferative repair, and fibrotic phases of ARDS. We further discuss how disease stage transitions, immunometabolic regulation, and ARDS heterogeneity shape these interaction networks. Based on these findings, we present an AEC-centered dynamic reprogramming framework that organizes current evidence on how epithelial-immune interactions change during ARDS progression. We also discuss candidate biomarkers, approaches for clinical stage and phenotype identification, therapeutic opportunities, and current evidence limitations, aiming to provide a conceptual framework for stage-specific and precision interventions in ARDS. We further contextualize existing and controversial immunomodulatory strategies, including corticosteroids and IL-6/IL-1 blockade, within this dynamic framework to illustrate how disease stage and patient phenotype may influence therapeutic responses. Throughout the review, we distinguish evidence derived from experimental models from observational data in human ARDS and separately identify human interventional evidence and therapies supported by current clinical guidelines.

Related

  1. Cyclic stretch increases glucose uptake and pro-inflammatory response in rat alveolar epithelial type II cells
    Jorge M. C. Ferreira, Robert Huhle, Sabine Müller +2
    Frontiers in physiologyPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. HDAC3 drives type II alveolar epithelial barrier dysfunction via MKP1 deacetylation in radiation‐induced lung injury
    Boyang Li, Ning Li, Rui Xiong +7
    Clinical and Translational MedicinePeer-reviewedCC BY 4.0Full textMedical imaging & radiologyPMC
  3. Single-cell lung eQTL colocalization implicates alveolar epithelial regulatory effects at COPD lung-function loci
    R. B. Eberle, H. Rijhwani, C. Tern +2
    medRxivPreprintCC BY-NC-NDFull textHuman geneticsmedRxiv
  4. Efficacy of polymyxin B against different pathogens in carbapenem-resistant gram-negative bacterial pneumonia and its relationship with alveolar epithelial lining fluid concentration: a prospective cohort study
    Xuanxi Huang, Mengjie Song, Xueyong Li +7
    Annals of MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineDOAJPMC
  5. TACC3-driven translation reprogramming dictates susceptibility or tolerance to mitotic stress
    O. Saatci, A. Hernandez-Corchado, A. Aguilar-Mahecha +12
    bioRxivPreprintCC BYFull textOncologybioRxiv
BibTeX
@article{gao2026dynamic,
  title = {{Dynamic reprogramming of alveolar epithelial-immune cell interactions in ARDS: from mechanisms to clinical translation}},
  author = {Chang Gao and Qianlin Wang and Ziqi Tan and Yingying Yang and Longxiang Su and Yun Long and Li Wen},
  journal = {Critical Care},
  year = {2026},
  month = aug,
  doi = {10.1186/s13054-026-06265-6},
  url = {https://doi.org/10.1186/s13054-026-06265-6},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Dynamic reprogramming of alveolar epithelial-immune cell interactions in ARDS: from mechanisms to clinical translation
AU  - Chang Gao
AU  - Qianlin Wang
AU  - Ziqi Tan
AU  - Yingying Yang
AU  - Longxiang Su
AU  - Yun Long
AU  - Li Wen
PY  - 2026
DA  - 2026/08/16
JO  - Critical Care
DO  - 10.1186/s13054-026-06265-6
UR  - https://doi.org/10.1186/s13054-026-06265-6
AB  - Acute respiratory distress syndrome (ARDS) is a life-threatening syndrome characterized by disruption of the alveolar-capillary barrier and refractory hypoxemia. Despite advances in supportive care, effective targeted therapies remain lacking. A major challenge to therapeutic success is the marked heterogeneity of ARDS, in which distinct biological mechanisms may drive different etiologies, inflammatory subphenotypes, and disease stages. Increasing evidence suggests that alveolar epithelial cells (AECs) are not merely passive targets of injury but active regulators of immune responses. Dynamic interactions between AECs and macrophages, neutrophils, and lymphocytes occur throughout the course of ARDS and contribute to inflammatory amplification, tissue repair, and aberrant remodeling. In this review, we summarize epithelial-immune interaction patterns across the inflammatory exudative, proliferative repair, and fibrotic phases of ARDS. We further discuss how disease stage transitions, immunometabolic regulation, and ARDS heterogeneity shape these interaction networks. Based on these findings, we present an AEC-centered dynamic reprogramming framework that organizes current evidence on how epithelial-immune interactions change during ARDS progression. We also discuss candidate biomarkers, approaches for clinical stage and phenotype identification, therapeutic opportunities, and current evidence limitations, aiming to provide a conceptual framework for stage-specific and precision interventions in ARDS. We further contextualize existing and controversial immunomodulatory strategies, including corticosteroids and IL-6/IL-1 blockade, within this dynamic framework to illustrate how disease stage and patient phenotype may influence therapeutic responses. Throughout the review, we distinguish evidence derived from experimental models from observational data in human ARDS and separately identify human interventional evidence and therapies supported by current clinical guidelines.
SN  - 1364-8535
SN  - 1466-609X
ER  -